CAR-T 细胞治疗NHL毒副作用临床管理专家共识

2021-02-15 中国研究型医院学会 转化医学杂志.2021.10(1):1-11.

嵌合抗原受体修饰T 细胞( Chimeric Antigen Receptor T Cell,CAR T) 已成为难治性复发B 细胞非霍奇金淋巴瘤( Non-Hodgkin's Lymphoma,NH

中文标题:

CAR-T 细胞治疗NHL毒副作用临床管理专家共识

发布机构:

中国研究型医院学会

发布日期:

2021-02-15

简要介绍:

嵌合抗原受体修饰T 细胞( Chimeric Antigen Receptor T Cell,CAR T) 已成为难治性复发B 细胞非霍奇金淋巴瘤( Non-Hodgkin's Lymphoma,NHL) 的有效治疗手段,此背景下其毒副作用的临床处置规范化也势在必行。中国研究型医院学会生物治疗学专委会组织专家编写此共识于2020 年11 月完成,旨在为临床工作人员判别与处理CAR T 细胞治疗NHL 相关毒副作用提供更为全面、规范的处置原则和探索性处理建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=CAR_T细胞治疗NHL毒副作用临床管理专家共识_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=3b4b21c00206e051, title=CAR-T 细胞治疗NHL毒副作用临床管理专家共识, enTitle=, guiderFrom=转化医学杂志.2021.10(1):1-11., authorId=0, author=, summary=嵌合抗原受体修饰T 细胞( Chimeric Antigen Receptor T Cell,CAR T) 已成为难治性复发B 细胞非霍奇金淋巴瘤( Non-Hodgkin's Lymphoma,NH, cover=https://img.medsci.cn/202138/1615138100973_2020535.jpg, journalId=0, articlesId=null, associationId=1023, associationName=中国研究型医院学会, associationIntro=中国研究型医院学会,英文名称Chinese Research Hospital Association(CRHA),是经国家民政部正式批复并登记注册的全国性一级学会,是独立的法人社团。中国研究型医院学会是由以探索和建设研究型医院为目标的具有医疗服务、科学研究和临床教学&ldquo;三位一体&rdquo;功能的医疗机构,以及从事研究型医院理论与实践研究的人员自愿结成的全国性、专业性、学术性、非营利性社会组织。, copyright=0, guiderPublishedTime=Mon Feb 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>嵌合抗原受体修饰T 细胞( Chimeric Antigen Receptor T Cell,CAR T) 已成为难治性复发B 细胞非霍奇金淋巴瘤( Non-Hodgkin's Lymphoma,NHL) 的有效治疗手段,此背景下其毒副作用的临床处置规范化也势在必行。中国研究型医院学会生物治疗学专委会组织专家编写此共识于2020 年11 月完成,旨在为临床工作人员判别与处理CAR T 细胞治疗NHL 相关毒副作用提供更为全面、规范的处置原则和探索性处理建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=29189, tagName=CAR-T细胞)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=29189, guiderKeyword=CAR-T细胞, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8973, appHits=94, showAppHits=0, pcHits=958, showPcHits=8879, likes=0, shares=10, comments=5, approvalStatus=1, publishedTime=Mon Mar 08 01:49:10 CST 2021, publishedTimeString=2021-02-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 08 01:28:29 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 04:54:16 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=CAR_T细胞治疗NHL毒副作用临床管理专家共识_.pdf)])
CAR_T细胞治疗NHL毒副作用临床管理专家共识_.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=953643, encodeId=4dff9536437c, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:24:36 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948856, encodeId=11849488564d, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/7fda5dd0dd3f4cc88875c2afd5fa0a09/f222d9c3ba03480d8af9b8119648b17e.jpg, createdBy=ab3660253, createdName=sowhat133, createdTime=Tue Mar 16 23:25:34 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946383, encodeId=666794638307, content=临床管理专家共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:57:16 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-04-03 446993560

    棒棒哒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=953643, encodeId=4dff9536437c, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:24:36 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948856, encodeId=11849488564d, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/7fda5dd0dd3f4cc88875c2afd5fa0a09/f222d9c3ba03480d8af9b8119648b17e.jpg, createdBy=ab3660253, createdName=sowhat133, createdTime=Tue Mar 16 23:25:34 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946383, encodeId=666794638307, content=临床管理专家共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:57:16 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-16 sowhat133

    很不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=953643, encodeId=4dff9536437c, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:24:36 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948856, encodeId=11849488564d, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/7fda5dd0dd3f4cc88875c2afd5fa0a09/f222d9c3ba03480d8af9b8119648b17e.jpg, createdBy=ab3660253, createdName=sowhat133, createdTime=Tue Mar 16 23:25:34 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946383, encodeId=666794638307, content=临床管理专家共识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:57:16 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-08 科研科研科研

    临床管理专家共识

    0

拓展阅读

FDA开发嵌合抗原受体 T 细胞(CAR-T)产品的注意事项

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2022-03-15